Cardiovascular risk factors and HIV disease

AIDS Reviews

Volumn 13, Issue 2, 2011, Pages 119-129

  Fedele, Francesco ^a   Bruno, Noemi ^a   Mancone, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiretroviral therapy; Cardiovascular risk factors; Endothelial dysfunction; HIV infection; Inflammation

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN; C REACTIVE PROTEIN; CHOLESTEROL; D DIMER; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AGE; AGING; ANGINA PECTORIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EXERCISE; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; GLUCOSE INTOLERANCE; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; PHENOTYPE; REVIEW; RISK ASSESSMENT; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METHODOLOGY; PATHOPHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HIV INFECTIONS; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 80053068720     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Friis-Møller N, Sabin C, Weber R, et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
2. Lohse N, Hansen A, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95. (Pubitemid 351640011)
3. Stevn K, Grinspoon, Carl Grunfeld, et al. State of the Science Conference Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS Executive Summary. Circulation. 2008;118:198-210.
4. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J. 1991;121:1244-62.
5. Dzau V, Antman E, Black H, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-70. (Pubitemid 46018288)
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
7. Reusch J. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 2002;90:19-26G.
8. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. (Pubitemid 28213628)
9. Li R, Bensen J, Hutchinson R, et al. Family risk score of coronary heart disease (CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) Study and the NHLBI Family Heart Study. Genet Epidemiol. 2000;18:236-50. (Pubitemid 30164235)
10. Williams R, Hunt S, Heiss G, et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol. 2001;87:129-35. (Pubitemid 32057219)
11. Siegmund K, Province M, Higgins M, Williams R, Keller J, Todorov A. Modeling disease incidence rates in families. Epidemiology. 1998;9:557-62. (Pubitemid 28387958)
12. Snowden C, McNamara P, Garrison R, Feinleib M, Kannel W, Epstein F. Predicting coronary heart disease in siblings-a multivariate assessment: the Framingham Heart Study. Am J Epidemiol. 1982;115:217-22. (Pubitemid 12182300)
13. Khaw K-T, Barrett-Connor E. Family history of heart attack: a modifiable risk factor? Circulation 1986;74:239-44. (Pubitemid 16072118)
14. Steinberg D, Witztum J. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 2002;105:2107-11. (Pubitemid 34465275)
15. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001;103:1955-60. (Pubitemid 32322222)
16. Barter P, Nicholls S, Rye K, Anantharamaiah G, Navab M, Fogelman A. Antiinflammatory properties of HDL. Circ Res. 2004;95:764-72. (Pubitemid 39390578)
17. Florentin M, Liberopoulos E, Wierzbicki A, Mikhailidis D. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370-8. (Pubitemid 351787103)
18. Cannon C, Braunwald E, McCabe C, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. (Pubitemid 38477774)
19. LaRosa J, Grundy S, Waters D, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. (Pubitemid 40471450)
20. Nissen S, Tuzcu E, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38. (Pubitemid 40075678)
21. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39. (Pubitemid 38924592)
22. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943-9.
23. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated levels of lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 1996;77:1179-84. (Pubitemid 26186958)
24. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil: experience from the Helsinki Heart Study. Circulation. 1995;92:1779-85.
25. Hodis H, Mack W, Azen S, et al. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42-9.
26. Grundy S, Vega G. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Arch Intern Med. 1992;152:28-34.
27. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma level of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;31:1557-63. (Pubitemid 16177394)
28. Abdel-Maksoud M, Sazonov V, Gutkin S, Hokanson J. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. J Cardiovasc Pharmacol. 2008;51:331-51. (Pubitemid 351572232)
29. Gibbons G, Dzau V. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-8. (Pubitemid 24139238)
30. Dzau V, Antman E, Black H, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: Part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation. 2006;114;2850-70. (Pubitemid 46018288)
31. Dormandy J, Charbonnel B, Eckland D, et al. PROACTIVE Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROACTIVE Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. (Pubitemid 41416583)
32. Lindholm L, Ibsen H, Dahlöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-10. (Pubitemid 34286537)
33. Pearson T, Mensah G, Alexander R, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511. (Pubitemid 36158056)
34. Julien P, Vohl M-C, Gaudet D, et al. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes. 1997;46:2063-8. (Pubitemid 27512097)
35. Grundy S. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-8. (Pubitemid 34615135)
36. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-43. (Pubitemid 34212626)
37. Prasad D, Kabir Z, Dash A, Das B. Smoking and cardiovascular health: A review of the epidemiology, pathogenesis, prevention and control of tobacco. Indian J Med Sci. 2009;63:520-33.
38. Ridker P. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9. (Pubitemid 36158034)
39. Ridker P, Danielson E, Fonseca F, et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-207.
40. Elliott P, Chambers J, Zhang W, et al. Genetic loci associated with creactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37-48.
41. Malinow M, Bostom A, Krauss R. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation. 1999;99: 178-82. (Pubitemid 29035977)
42. Giles W, Croft J, Greenlund K, Ford E, Kittner S. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: results from the Third National Health and Nutrition Examination Survey. Am Heart J. 2000;139:446-53. (Pubitemid 30149194)
43. HOPE2 investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-77.
44. Devereux R, Roman M. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res. 1999;22:1-9. (Pubitemid 29192362)
45. Victor J. Dzau M, Elliott M, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes Part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114;2871-91.
46. Mensah G, Pappas T, Koren M, Ulin R, Laragh J, Devereux R. Comparison of classification of the severity of hypertension by blood pressure level and by World Health Organization criteria in the prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993;11:1429-40. (Pubitemid 24008492)
47. Mancini G, Dahlöf B, Díez J. Surrogate markers for cardiovascular disease: structural markers. Circulation. 2004;109(Suppl I):IV22-30.
48. Ferri N, Paoletti R, Corsini A. Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Curr Opin Lipidol. 2006;17:495-501. (Pubitemid 44372679)
49. Bots M, Baldassarre D, Simon A, et al. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007;28:398-406. (Pubitemid 47343565)
50. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
51. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52. (Pubitemid 39208455)
52. Savès M, Chene G, Ducimetière P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37:292-8. (Pubitemid 36930361)
53. Friis-Møller N, Reiss P, Sabin C, et al. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35. (Pubitemid 46658704)
54. Triant V, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-12. (Pubitemid 47037350)
55. Monforte A, Pradier C, Morfeldt L, et al. DAD Study Group. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS. 2003;17:1179-93. (Pubitemid 36667761)
56. Savès M, Chêne G, Ducimetière P, et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37:292-8. (Pubitemid 36930361)
57. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients, part II: gender differences. Eur J Med Res. 2004;9:55-60.
58. Kaplan R, Kingsley L, Sharrett A, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007;45:1074-81. (Pubitemid 47580361)
59. Joy T, Keogh H, Hadigan C, et al. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS. 2007;21:1591-600. (Pubitemid 47075480)
60. Law M, Friis-Møller N, El-Sadr W, et al. D:A:D Study Group. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med. 2006;7:218-30.
61. Grunfeld C, Pang M, Doerrler W, Shigenaga J, Jensen P, Feingold K. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-52.
62. Constans J, Pellegrin J, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24:416-20. (Pubitemid 24201271)
63. Ho J, Hsue P. Cardiovascular manifestations of HIV infection. Heart. 2009;95:1193-202.
64. Rose H, Hoy J, Woolley I, et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2008;199:79-86. (Pubitemid 351842701)
65. Badiou S, De Boever C, Dupuy A, et al. Decrease in LDL size in HIVpositive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis. 2003;168:107-13. (Pubitemid 36555817)
66. El-Sadr W, Mullin C, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114-21. (Pubitemid 40425975)
67. Gupta S, Johnson R, Saha C, et al. Improvement in HIV-related endothelial dysfunction using the anti-inflammatory agent salsalate: a pilot study. AIDS. 2008;22:653-5. (Pubitemid 351640600)
68. Calmy A, Gayet-Ageron A, Montecucco F, et al. STACCATO Study Group. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929-39.
69. Leghmari K, Bennasser Y, Tkaczuk J, Bahraoui E. HIV-1 Tat protein induces IL-10 production by an alternative TNF-alpha-independent pathway in monocytes: role of PKC-delta and p38 MAP kinase. Cell Immunol. 2008;253:45-53.
70. Lehmann M, Walter S, Ylisastigui L, et al. Extracellular HIV-1 Nef increases migration of monocytes. Exp Cell Res. 2006;312:3659-68. (Pubitemid 44470783)
71. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368:459-65. (Pubitemid 44142768)
72. Conaldi P, Serra C, Dolei A, et al. Productive HIV-1 infection of human vascular endothelial cells requires cell proliferation and is stimulated by combined treatment with interleukin-1 beta plus tumor necrosis factoralpha. J Med Virol. 1995;47:355-63. (Pubitemid 26022312)
73. Bukrinsky M, Sviridov D. Human immunodeficiency virus infection and macrophage cholesterol metabolism. J Leukoc Biol. 2006;80:1044-51. (Pubitemid 44646310)
74. Maggi P, Lillo A, Perilli F, et al. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS. 2004;18:1023-8. (Pubitemid 38591193)
75. Passalaris J, Sepkowitz K, Glesby M. Coronary artery disease and HIV infection. Clin Infect Dis. 2000;31:787-97.
76. Stein J. Cardiovascular risks of antiretroviral therapy. N Engl J Med. 2007:356;17.
77. Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-9. (Pubitemid 36549708)
78. Dube M, Zackin R, Tebas P, et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a study of ACTG 384. Antivir Ther. 2002;7:L18.
79. Bastard J, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet. 2002;359:1026-31. (Pubitemid 34286541)
80. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes. 2001;50:1378-88. (Pubitemid 32500171)
81. El-Sadr W, Lundgren J, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96. (Pubitemid 44837777)
82. Phillips A, Carr A, Neuhaus J, et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther. 2008;13:177-87. (Pubitemid 351535369)
83. Lenhard J, Furfine E, Jain R, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-9.
84. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS. 2003;17:2437-44. (Pubitemid 38393315)
85. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus infected men receiving highly active antiretroviral therapy. Metabolism. 2002;51:1143-7.
86. Roche R, Poizot-Martin I, Yazidi C, et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS. 2002;16:13-20. (Pubitemid 34062177)
87. Zietz C, Hotz B, Sturzl M, Rauch E, Penning R, Lohrs U. Aortic endothelium in HIV-1 infection: chronic injury, activation, and increased leukocyte adherence. Am J Pathol. 1996;149:1887-98. (Pubitemid 26415209)
88. Tien P, Benson C, Zolopa A, et al. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol. 2006;163:860-9.
89. Sitia G, De Bona A, Bagaglio S, et al. Naive HIV/HCV-coinfected patients have higher intrahepatic pro-inflammatory cytokines than coinfected patients treated with antiretroviral therapy. Antivir Ther. 2006;11:385-9. (Pubitemid 43823558)
90. Mynarcik D, McNurlan M, Steigbigel R, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2000;25:312-21. (Pubitemid 32107162)
91. Reiss P, Casula M, de Ronde A, Weverling G, Goudsmit J, Lange J. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+ zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors. HIV Med. 2004;5:11-4. (Pubitemid 38219975)
92. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS. 2003;17:1329-38. (Pubitemid 36819847)
93. D:A:D Study Group, Friis-Moller N, Reiss P, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356: 1723-35.
94. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in hiv-infected adults. N Engl J Med. 2005;352:1.
95. Prineas R, Roediger M, Carr A, et al. Effect of alternate treatment protocols on the incidence of electrocardiographic abnormalities among HIV infected adults in the SMART trial. Presented at: 4th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; Sydney, Australia. 2007 [Abstract].
96. Aberg J. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr. 2009;50:54-64.
97. Hsue P, Squires K, Bolger A, et al. Working Group 4. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation. 2008;118;e41-7.
98. Wilson P, D'Agostino R, Levy D, Belanger A, Silbershatz H, Kannel W. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-47. (Pubitemid 28213628)
99. Hsue P, Hunt P, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275-83. (Pubitemid 44789529)
100. Hsue P, Lo J, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603-8. (Pubitemid 38451715)
101. Hsue P, Hunt P, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275-83. (Pubitemid 44789529)
102. Tien P, Benson C, Zolopa A, et al. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol. 2006;163:860-9.
103. Friis-Møller N, Thiébaut R, Reiss P, et al. D:A:D Study Group. Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: the D:A:D CHD Risk Equation. Paper presented at: 14th CROI; February, 2007; Los Angeles, CA.
104. Currier J, Lundgren J, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118:e29-35.
105. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009; 1-161. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
106. Stein J, Hadigan C. Prevention strategies for cardiovascular disease in HIV-infected patients. Circulation. 2008;118;e54-60.